CA3210001A1 - Microsphere formulations comprising btk inhibitors and methods for making and using the same - Google Patents
Microsphere formulations comprising btk inhibitors and methods for making and using the same Download PDFInfo
- Publication number
- CA3210001A1 CA3210001A1 CA3210001A CA3210001A CA3210001A1 CA 3210001 A1 CA3210001 A1 CA 3210001A1 CA 3210001 A CA3210001 A CA 3210001A CA 3210001 A CA3210001 A CA 3210001A CA 3210001 A1 CA3210001 A1 CA 3210001A1
- Authority
- CA
- Canada
- Prior art keywords
- polymer
- microsphere
- lactide
- microsphere formulation
- btk inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 174
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 229940124291 BTK inhibitor Drugs 0.000 title claims abstract description 63
- 238000009472 formulation Methods 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 34
- 229920000642 polymer Polymers 0.000 claims description 119
- 239000003814 drug Substances 0.000 claims description 53
- 229940079593 drug Drugs 0.000 claims description 49
- 239000002245 particle Substances 0.000 claims description 41
- 229920002988 biodegradable polymer Polymers 0.000 claims description 39
- 239000004621 biodegradable polymer Substances 0.000 claims description 39
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 36
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 35
- 229960001507 ibrutinib Drugs 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 17
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 14
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 14
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 14
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 13
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 230000036210 malignancy Effects 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 8
- 239000000178 monomer Substances 0.000 claims description 7
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 4
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 239000012071 phase Substances 0.000 claims 6
- 239000000839 emulsion Substances 0.000 claims 4
- 239000008346 aqueous phase Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 6
- 238000013265 extended release Methods 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 65
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 25
- 239000002904 solvent Substances 0.000 description 17
- 239000002253 acid Substances 0.000 description 15
- 239000013256 coordination polymer Substances 0.000 description 11
- 229920000747 poly(lactic acid) Polymers 0.000 description 11
- 230000001186 cumulative effect Effects 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 239000000872 buffer Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000012510 hollow fiber Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 4
- ABSXPNGWJFAPRT-UHFFFAOYSA-N benzenesulfonic acid;n-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 ABSXPNGWJFAPRT-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- RNOAOAWBMHREKO-QFIPXVFZSA-N (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C(C=C)(=O)N1CCC(CC1)[C@@H]1CCNC=2N1N=C(C=2C(=O)N)C1=CC=C(C=C1)OC1=CC=CC=C1 RNOAOAWBMHREKO-QFIPXVFZSA-N 0.000 description 2
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 2
- SEJLPXCPMNSRAM-GOSISDBHSA-N 6-amino-9-[(3r)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one Chemical compound C1N(C(=O)C#CC)CC[C@H]1N1C(=O)N(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C2=C(N)N=CN=C21 SEJLPXCPMNSRAM-GOSISDBHSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- UNHZLHSLZZWMNP-LLVKDONJSA-N NC(=O)c1ccc([C@@H]2CCCN(C2)C(=O)C=C)c2cc[nH]c12 Chemical compound NC(=O)c1ccc([C@@H]2CCCN(C2)C(=O)C=C)c2cc[nH]c12 UNHZLHSLZZWMNP-LLVKDONJSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 2
- 229950009821 acalabrutinib Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- QUIWHXQETADMGN-UHFFFAOYSA-N evobrutinib Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1C=1C(N)=NC=NC=1NCC1CCN(C(=O)C=C)CC1 QUIWHXQETADMGN-UHFFFAOYSA-N 0.000 description 2
- 229950003411 evobrutinib Drugs 0.000 description 2
- 229950009618 fenebrutinib Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- -1 poly(L-lactide) Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229950002089 spebrutinib Drugs 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229950007153 zanubrutinib Drugs 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 1
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000004085 CLL/SLL Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 1
- 206010072757 chronic spontaneous urticaria Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/08—Simple coacervation, i.e. addition of highly hydrophilic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Extended-release microsphere formulations comprising a BTK inhibitor are provided. In one aspect, the microsphere formulations are characterized in that the BTK inhibitor is released in vivo in humans over a period of from about 7 to about 28 days. Methods for making and using the formulations are also provided.
Description
2 PCT/US2022/070910 MICROSPHERE FORMULATIONS COMPRISING BTK INHIBITORS AND
METHODS FOR MAKING AND USING THE SAME
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Patent Application No.
63/156,020, filed on March 3, 2021, which is incorporated by reference herein in its entirety.
BACKGROUND
[0002] B-cells account for up to 25% of all cells in some cancers. By inhibiting the Bruton's Tyrosine Kinase ("BTK") enzyme involved in B-cell receptor signaling, BTK
inhibitors cause detachment of malignant B-cells from cancer sites into blood, which results in cell death. BTK
inhibition reduces the proliferation of malignant B-cells and decreases the survival of malignant B-cells.
METHODS FOR MAKING AND USING THE SAME
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Patent Application No.
63/156,020, filed on March 3, 2021, which is incorporated by reference herein in its entirety.
BACKGROUND
[0002] B-cells account for up to 25% of all cells in some cancers. By inhibiting the Bruton's Tyrosine Kinase ("BTK") enzyme involved in B-cell receptor signaling, BTK
inhibitors cause detachment of malignant B-cells from cancer sites into blood, which results in cell death. BTK
inhibition reduces the proliferation of malignant B-cells and decreases the survival of malignant B-cells.
[0003] Ibrutinib (chemical formula C25H24N602; CAS Number 936563-96-1), characterized by the general structure:
N
ii N N N
is a BTK inhibitor. Ibrutinib, alone and in combination with other drugs, has been approved by the U.S. Food and Drug Administration (the "FDA") for the treatment of mantle cell lymphoma ("MCL"), chronic lymphocytic leukemia ("CLL"), Waldenstrom' s macroglobulinemia, small lymphocytic lymphoma ("SLL"), relapsed/refractory marginal zone lymphoma in patients who require systemic therapy and have received at least one prior anti-CD20-based therapy, and graft-versus-host disease, among other diseases.
N
ii N N N
is a BTK inhibitor. Ibrutinib, alone and in combination with other drugs, has been approved by the U.S. Food and Drug Administration (the "FDA") for the treatment of mantle cell lymphoma ("MCL"), chronic lymphocytic leukemia ("CLL"), Waldenstrom' s macroglobulinemia, small lymphocytic lymphoma ("SLL"), relapsed/refractory marginal zone lymphoma in patients who require systemic therapy and have received at least one prior anti-CD20-based therapy, and graft-versus-host disease, among other diseases.
[0004] Two other BTK inhibitors have been approved by the FDA:
acalabrutinib (approved for treatment of relapsed MCL) and zanubrutinib (approved for treatment of MCL). Several other drugs that inhibit BTK are in clinical trials, including evobrutinib for multiple sclerosis; ABBV-105 for systemic lupus erythematosus; fenebrutinib for rheumatoid arthritis, systemic lupus erythematosus, and chronic spontaneous urticaria; GS-4059 for non-Hodgkin's lymphoma and/or CLL; Spebrutinib (AVL-292, CC-292); and HM71224 for autoimmune diseases.
acalabrutinib (approved for treatment of relapsed MCL) and zanubrutinib (approved for treatment of MCL). Several other drugs that inhibit BTK are in clinical trials, including evobrutinib for multiple sclerosis; ABBV-105 for systemic lupus erythematosus; fenebrutinib for rheumatoid arthritis, systemic lupus erythematosus, and chronic spontaneous urticaria; GS-4059 for non-Hodgkin's lymphoma and/or CLL; Spebrutinib (AVL-292, CC-292); and HM71224 for autoimmune diseases.
[0005] All of the currently approved BTK inhibitors are oral formulations.
Oral formulations may have several disadvantages. For example, oral formulations may require closely timed, successive dosages under the supervision of a physician. Further, some BTK
inhibitors may have low and variable oral bioavailability. For example, ibrutinib may have an oral bioavailability of only 2.9% in the fasted state, but this can vary from patient to patient.
Oral formulations may have several disadvantages. For example, oral formulations may require closely timed, successive dosages under the supervision of a physician. Further, some BTK
inhibitors may have low and variable oral bioavailability. For example, ibrutinib may have an oral bioavailability of only 2.9% in the fasted state, but this can vary from patient to patient.
[0006] A need exists for a high-bioavailability formulation comprising a BTK inhibitor that may be administered by a long-acting, sustained release injection, without the need for patients to administer closely timed, successive dosages under supervision from their physician.
SUMMARY
SUMMARY
[0007] Microsphere formulations comprising a BTK inhibitor are provided.
The microsphere formulations comprise polymer microspheres, each polymer microsphere comprising: (i) a BTK
inhibitor; and (ii) a biodegradable polymer, wherein each polymer microsphere comprises a drug load of the BTK inhibitor of greater than 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of less than 110 i_tm (D5o). In another aspect, the microsphere formulations are characterized in that they have a low initial burst release, that is, not more than 50% of the BTK inhibitor is released within about 4 hours of injection into a subject.
The microsphere formulations comprise polymer microspheres, each polymer microsphere comprising: (i) a BTK
inhibitor; and (ii) a biodegradable polymer, wherein each polymer microsphere comprises a drug load of the BTK inhibitor of greater than 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of less than 110 i_tm (D5o). In another aspect, the microsphere formulations are characterized in that they have a low initial burst release, that is, not more than 50% of the BTK inhibitor is released within about 4 hours of injection into a subject.
[0008] In one aspect, the microsphere formulations may be made by a method, the method comprising: (A) mixing: (i) the biodegradable polymer; (ii) a primary solvent;
and (iii) a BTK
inhibitor, to form a dispersed phase; (B) mixing: (i) water; and (ii) a surfactant, to form a continuous phase; and (C) combining the dispersed phase with the continuous phase in a homogenizer.
and (iii) a BTK
inhibitor, to form a dispersed phase; (B) mixing: (i) water; and (ii) a surfactant, to form a continuous phase; and (C) combining the dispersed phase with the continuous phase in a homogenizer.
[0009] In one aspect, a method for treating cancer, including a B-cell malignancy, is provided.
The method may comprise administering by intramuscular or subcutaneous injection to a patient in need thereof a microsphere formulation made according to the methods described herein.
The method may comprise administering by intramuscular or subcutaneous injection to a patient in need thereof a microsphere formulation made according to the methods described herein.
[0010] In another aspect, use is disclosed of a microsphere formulation comprising polymer microspheres, each polymer microsphere comprising: (i) a BTK inhibitor; and (ii) a biodegradable polymer, wherein each polymer microsphere comprises a drug load of the BTK
inhibitor of greater than 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of less than 110 i_tm (D5o), in the manufacture of a medicament for the treatment of cancer, including a B-cell malignancy.
inhibitor of greater than 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of less than 110 i_tm (D5o), in the manufacture of a medicament for the treatment of cancer, including a B-cell malignancy.
[0011] In another aspect, a microsphere formulation comprising polymer microspheres, each polymer microsphere comprising: (i) a BTK inhibitor; and (ii) a biodegradable polymer, wherein each polymer microsphere comprises a drug load of the BTK inhibitor of greater than 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of less than 110 i_tm (D5o), is provided for use as a medicament for the treatment of cancer, including a B-cell malignancy.
[0012] In another aspect, a kit is provided, the kit comprising polymer microspheres, each polymer microsphere comprising: (i) a BTK inhibitor; and (ii) a biodegradable polymer, wherein each polymer microsphere comprises a drug load of the BTK inhibitor of greater than 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of less than 110 i_tm (D5o).
BRIEF DESCRIPTION OF THE FIGURES
BRIEF DESCRIPTION OF THE FIGURES
[0013] Figure 1 is a schematic depicting a method for making BTK inhibitor-encapsulated polymer microspheres.
[0014] Figure 2 is a graph showing in vitro cumulative ibrutinib release over time from ibrutinib-encapsulating polymer microspheres comprising a 50:50 poly (D,L-lactide-co-glycolide) ("PLGA") as the biodegradable polymer.
[0015] Figure 3 is a graph showing in vitro cumulative ibrutinib release over time from ibrutinib-encapsulating polymer microspheres comprising a 75:25 PLGA with an inherent viscosity ("IV") of 0.26 dL/g as the biodegradable polymer.
[0016] Figure 4 is a graph showing in vitro cumulative ibrutinib release over time from ibrutinib-encapsulating polymer microspheres comprising a 75:25 PLGA with IVs between 0.41 dL/g and 0.70 dL/g as the biodegradable polymer.
[0017] Figure 5 is a graph showing in vitro cumulative ibrutinib release over time from ibrutinib-encapsulating polymer microspheres comprising an 85:15 PLGA as the biodegradable polymer.
[0018] Figure 6 is a graph showing in vitro cumulative ibrutinib release over time from ibrutinib-encapsulating polymer microspheres comprising a poly(D,L-lactide) ("PLA") as the biodegradable polymer.
DETAILED DESCRIPTION
DETAILED DESCRIPTION
[0019] Microsphere formulations comprising a BTK inhibitor are provided.
The microsphere formulations comprise polymer microspheres, each polymer microsphere comprising: (i) a BTK
inhibitor; and (ii) a biodegradable polymer, wherein each polymer microsphere comprises a drug load of the BTK inhibitor of greater than 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of less than 110 jim (D5o). In another aspect, the microsphere formulations are characterized in that they have a low initial burst release, that is, not more than 20% of the BTK inhibitor is released within about 24 hours of injection into a subject.
The microsphere formulations comprise polymer microspheres, each polymer microsphere comprising: (i) a BTK
inhibitor; and (ii) a biodegradable polymer, wherein each polymer microsphere comprises a drug load of the BTK inhibitor of greater than 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of less than 110 jim (D5o). In another aspect, the microsphere formulations are characterized in that they have a low initial burst release, that is, not more than 20% of the BTK inhibitor is released within about 24 hours of injection into a subject.
[0020] In one aspect, the microsphere formulations may be made by a method, the method comprising: (A) mixing: (i) the biodegradable polymer; (ii) a primary solvent;
and (iii) a BTK
inhibitor, to form a dispersed phase; (B) mixing: (i) water; and (ii) a surfactant, to form a continuous phase; and (C) combining the dispersed phase with the continuous phase in a homogenizer.
BTK inhibitors
and (iii) a BTK
inhibitor, to form a dispersed phase; (B) mixing: (i) water; and (ii) a surfactant, to form a continuous phase; and (C) combining the dispersed phase with the continuous phase in a homogenizer.
BTK inhibitors
[0021] In one aspect, the BTK inhibitor is selected from the group comprising, consisting essentially of, or consisting of ibrutinib, acalabrutinib, zanubrutinib, evobrutinib, ABBV-105, fenebrutinib, GS-4059, or spebrutinib, or combinations thereof
[0022] In one aspect, the composition consists essentially of ibrutinib. In one aspect, the ibrutinib is supplied by ScinoPharm or MSN. In one aspect, the ibrutinib is hydrophobic. In one aspect, the ibrutinib is supplied as a free base. In another aspect, the ibrutinib is supplied as a pharmaceutically acceptable salt. In one aspect, the ibrutinib is characterized by an aqueous solubility of <2.5 mg/g. In one aspect, the ibrutinib is characterized by a solubility in dichloromethane ("DCM") of >300 mg/g. In one aspect, the ibrutinib is characterized by a pKa of about 3.74.
[0023] The BTK inhibitor may be in various polymorphic forms. Polymorphic forms may include hemihydrates, monohydrates, dihydrates, and other polymorphic forms as known in the art. Salts may include hydrochloride, sulfate, acetate, phosphate, diphosphate, chloride, maleate, citrate, mesylate, nitrate, tartrate, gluconate, or other salts as known in the art. In one aspect, the BTK inhibitor is in an amorphous form.
[0024] In an aspect wherein the BTK inhibitor comprises ibrutinib or another BTK inhibitor with similar solubility characteristics, a complex salt may be used to decrease solubility, such as, for example, palmitate, benzoic acid, tosylic acid, camphor-sulfonic acid, or other salt complexes as one of skill in the art can readily envision.
Biodegradable Polymers
Biodegradable Polymers
[0025] In one aspect, the dispersed phase may include a biodegradable polymer, such as a PLGA or a PLA, although it is contemplated that other suitable biodegradable polymers may be used. The biodegradable polymer may be hydrophobic or hydrophilic.
[0026] In some aspects, the biodegradable polymer comprises a PLGA. In one aspect, the PLGA comprises a lactide:glycolide ratio of 50:50, 75:25, or 85:15. In one aspect, the PLGA is acid-terminated. In one aspect, the PLGA is ester-terminated. In one aspect, the PLGA has an IV
of from about 0.1 dL/g to about 0.8 dL/g, including from about 0.1 dL/g to about 0.3 dL/g, from about 0.16 dL/g to about 0.24 dL/g, from about 0.2 dL/g to about 0.4 dL/g, from about 0.4 dL/g to about 0.6 dL/g, from about 0.6 dL/g to about 0.8 dL/g, about 0.20 dL/g, 0.26 dL/g, 0.41 dL/g, 0.56 dL/g, 0.66 dL/g, 0.7 dL/g, and any value or range between any two of those IV
values.
of from about 0.1 dL/g to about 0.8 dL/g, including from about 0.1 dL/g to about 0.3 dL/g, from about 0.16 dL/g to about 0.24 dL/g, from about 0.2 dL/g to about 0.4 dL/g, from about 0.4 dL/g to about 0.6 dL/g, from about 0.6 dL/g to about 0.8 dL/g, about 0.20 dL/g, 0.26 dL/g, 0.41 dL/g, 0.56 dL/g, 0.66 dL/g, 0.7 dL/g, and any value or range between any two of those IV
values.
[0027] In one aspect, the PLGA comprises Resomerg 502 H, poly(D,L-lactide-co-glycolide), acid terminated, lactide:glycolide 50:50, manufactured by Evonik, having IV =
0.20 ("502 H"). In one aspect, the PLGA comprises Resomerg 502, poly(D,L-lactide-co-glycolide), ester terminated, lactide:glycolide 50:50, manufactured by Evonik, having IV = 0.20 ("502"). In one aspect, the PLGA comprises ViatelTM DLG 7503 A, poly(D,L-lactide-co-glycolide), acid terminated, lactide:glycolide 75:25, manufactured by Ashland, having IV = 0.26 ("7503 A").
In one aspect, the PLGA comprises ViatelTM DLG 7503 E, poly(D,L-lactide-co-glycolide), ester terminated, lactide:glycolide 75:25, manufactured by Ashland, having IV = 0.26 ("7503 E").
In one aspect, the PLGA comprises ViatelTM DLG 7505 A, poly(D,L-lactide-co-glycolide), acid terminated, lactide:glycolide 75:25, manufactured by Ashland, having IV = 0.56 ("7505 A").
In one aspect, the PLGA comprises ViatelTM DLG 7505 E, poly(D,L-lactide-co-glycolide), ester terminated, lactide:glycolide 75:25, manufactured by Ashland, having IV = 0.41 ("7505 E").
In one aspect, the PLGA comprises ViatelTM DLG 7507 A, poly(D,L-lactide-co-glycolide), acid terminated, lactide:glycolide 75:25, manufactured by Ashland, having IV = 0.70 ("7507 A").
In one aspect, the PLGA comprises ViatelTM DLG 7507 E, poly(D,L-lactide-co-glycolide), ester terminated, lactide:glycolide 75:25, manufactured by Ashland, having IV = 0.66 ("7507 E").
In one aspect, the PLGA comprises ViatelTM DL 8503 A, poly(D,L-lactide-co-glycolide), acid terminated, lactide:glycolide 85:15, manufactured by Ashland, having IV = 0.24 ("8503 A").
In one aspect, the PLGA comprises ViatelTM DL 8503 E, poly(D,L-lactide-co-glycolide), ester terminated, lactide:glycolide 85:15, manufactured by Ashland, having IV = 0.25 ("8503 E").
0.20 ("502 H"). In one aspect, the PLGA comprises Resomerg 502, poly(D,L-lactide-co-glycolide), ester terminated, lactide:glycolide 50:50, manufactured by Evonik, having IV = 0.20 ("502"). In one aspect, the PLGA comprises ViatelTM DLG 7503 A, poly(D,L-lactide-co-glycolide), acid terminated, lactide:glycolide 75:25, manufactured by Ashland, having IV = 0.26 ("7503 A").
In one aspect, the PLGA comprises ViatelTM DLG 7503 E, poly(D,L-lactide-co-glycolide), ester terminated, lactide:glycolide 75:25, manufactured by Ashland, having IV = 0.26 ("7503 E").
In one aspect, the PLGA comprises ViatelTM DLG 7505 A, poly(D,L-lactide-co-glycolide), acid terminated, lactide:glycolide 75:25, manufactured by Ashland, having IV = 0.56 ("7505 A").
In one aspect, the PLGA comprises ViatelTM DLG 7505 E, poly(D,L-lactide-co-glycolide), ester terminated, lactide:glycolide 75:25, manufactured by Ashland, having IV = 0.41 ("7505 E").
In one aspect, the PLGA comprises ViatelTM DLG 7507 A, poly(D,L-lactide-co-glycolide), acid terminated, lactide:glycolide 75:25, manufactured by Ashland, having IV = 0.70 ("7507 A").
In one aspect, the PLGA comprises ViatelTM DLG 7507 E, poly(D,L-lactide-co-glycolide), ester terminated, lactide:glycolide 75:25, manufactured by Ashland, having IV = 0.66 ("7507 E").
In one aspect, the PLGA comprises ViatelTM DL 8503 A, poly(D,L-lactide-co-glycolide), acid terminated, lactide:glycolide 85:15, manufactured by Ashland, having IV = 0.24 ("8503 A").
In one aspect, the PLGA comprises ViatelTM DL 8503 E, poly(D,L-lactide-co-glycolide), ester terminated, lactide:glycolide 85:15, manufactured by Ashland, having IV = 0.25 ("8503 E").
[0028] In some aspects, the biodegradable polymer is a PLA. In one aspect, the PLA is acid-terminated. In one aspect, the PLA is ester-terminated. In one aspect, the PLA
has an IV of between about 0.1 dL/g and about 0.4 dL/g, including about 0.16 dL/g, about 0.18 dL/g, and about 0.32 dL/g, and any value or range between any two of those IV values.
has an IV of between about 0.1 dL/g and about 0.4 dL/g, including about 0.16 dL/g, about 0.18 dL/g, and about 0.32 dL/g, and any value or range between any two of those IV values.
[0029] In one aspect, the PLA comprises a ViatelTM DL 02 A, poly(D,L-lactide), acid terminated, manufactured by Ashland, having IV = 0.16 ("DL 02 A"). In one aspect, the PLA
comprises a ViatelTM DL 02 E, poly(L-lactide), ester terminated, manufactured by Ashland, having IV = 0.18 ("DL 02 E"). In one aspect, the PLA comprises a ViatelTM DL 03 A, poly(L-lactide), acid terminated, manufactured by Ashland, having IV = 0.32 ("DL 03 A").
comprises a ViatelTM DL 02 E, poly(L-lactide), ester terminated, manufactured by Ashland, having IV = 0.18 ("DL 02 E"). In one aspect, the PLA comprises a ViatelTM DL 03 A, poly(L-lactide), acid terminated, manufactured by Ashland, having IV = 0.32 ("DL 03 A").
[0030] In one aspect, the biodegradable polymer is mixed with the BTK
inhibitor to form microspheres, which are injectable and formulated to release the BTK inhibitor to the patient over the intended duration of release. In another aspect, the biodegradable polymer is used to encapsulate the BTK inhibitor into microspheres, which are injectable and formulated to release the BTK inhibitor to the patient over the intended duration of release, via a controlled rate of release from the spheres, or release from different spheres at different times based upon particle size, thickness of the biodegradable polymer encapsulating the BTK inhibitor, molecular weight of the biodegradable polymer, polymer composition such as co-monomer ratio, end-cap, and drug load, or combinations of such release-affecting factors.
Dispersed Phase
inhibitor to form microspheres, which are injectable and formulated to release the BTK inhibitor to the patient over the intended duration of release. In another aspect, the biodegradable polymer is used to encapsulate the BTK inhibitor into microspheres, which are injectable and formulated to release the BTK inhibitor to the patient over the intended duration of release, via a controlled rate of release from the spheres, or release from different spheres at different times based upon particle size, thickness of the biodegradable polymer encapsulating the BTK inhibitor, molecular weight of the biodegradable polymer, polymer composition such as co-monomer ratio, end-cap, and drug load, or combinations of such release-affecting factors.
Dispersed Phase
[0031] In one aspect, the dispersed phase comprises a primary solvent. In one aspect, the primary solvent comprises DCM. The dispersed phase may also include up to about 50% by weight of a co-solvent capable of optimizing the solubility of the BTK
inhibitor in the primary solvent. In one aspect, the co-solvent may be benzyl alcohol, dimethyl sulfoxide, dimethyl formamide, dimethyl acetamide, acetonitrile, ethanol, N-methyl pyrrolidone, ethyl acetate, or any other solvent that increases the solubility of the BTK inhibitor in the dispersed phase containing DCM. A microsphere is "essentially free" of organic solvent if the microsphere meets the standards set forth in the "ICH Harmonised Guideline, Impurities: Guideline for Residual Solvents Q3C(R8), Current Step 4 version dated 22 April 2021," which is incorporated herein by reference in its entirety.
Continuous Phase
inhibitor in the primary solvent. In one aspect, the co-solvent may be benzyl alcohol, dimethyl sulfoxide, dimethyl formamide, dimethyl acetamide, acetonitrile, ethanol, N-methyl pyrrolidone, ethyl acetate, or any other solvent that increases the solubility of the BTK inhibitor in the dispersed phase containing DCM. A microsphere is "essentially free" of organic solvent if the microsphere meets the standards set forth in the "ICH Harmonised Guideline, Impurities: Guideline for Residual Solvents Q3C(R8), Current Step 4 version dated 22 April 2021," which is incorporated herein by reference in its entirety.
Continuous Phase
[0032] The dispersed phase may be combined with an aqueous continuous phase that comprises water and, optionally, a buffer, a surfactant, or both.
[0033] In one aspect, the buffer may be added to the continuous phase to maintain a pH of the solution of about 7.0 to about 8Ø In one aspect, the buffer may be a phosphate buffer or a carbonate buffer. In one aspect, the buffer may be a 10 mM phosphate or carbonate buffer solution and may be used to create and maintain a system pH level of about 7.6.
[0034] The surfactant component may be present in the continuous phase in an amount of about 0.35% to about 1.0% by weight in water. In one aspect, the surfactant component comprises polyvinyl alcohol ("PVA") in a concentration of 0.35% by weight in water.
[0035] In some aspects, the dispersed phase flow rate to the homogenizer may be from about mL/min to about 30 mL/min, including about 20 mL/min and about 25 mL/min. In some aspects, the continuous phase flow rate to the homogenizer may be about 2 L/min. Thus, in one aspect, the continuous phase:dispersed phase ratio may be from about 66:1 to about 200:1, including about 100:1 and about 80:1. Larger scale batches may require higher flow rates.
[0036] The continuous phase may be provided at room temperature or above or below room temperature. In some aspects, the continuous phase may be provided at about 40 C, about 37 C, about 35 C, about 30 C, about 25 C, about 20 C, about 15 C, about 10 C, about 5 C, about 0 C, and any value or range between any two of those temperature values.
Homogenizer
Homogenizer
[0037] For brevity, and because the methods are equally applicable to either, the phrase "homogenizer" contemplates a system or apparatus that can homogenize the dispersed phase and the continuous phase, emulsify the dispersed phase and the continuous phase, or both, which systems and apparatuses are known in the art. For example, in one aspect, the homogenizer is an in-line SiIverson Homogenizer (commercially available from SiIverson Machines, Waterside UK) or a Levitronix BPS-i100 integrated pump system used, e.g., as described in U.S. Patent No.
11,167,256, which is incorporated by reference herein in its entirety. In one aspect, the homogenizer is a membrane emulsifier or a static mixer. In one aspect, the homogenizer runs at an impeller speed of about 1,000 to about 4,000 revolutions per minute ("RPM"), including about 2,000 RPM, about 3,000 RPM, and any value or range between any two of those RPM values.
Drug Load
11,167,256, which is incorporated by reference herein in its entirety. In one aspect, the homogenizer is a membrane emulsifier or a static mixer. In one aspect, the homogenizer runs at an impeller speed of about 1,000 to about 4,000 revolutions per minute ("RPM"), including about 2,000 RPM, about 3,000 RPM, and any value or range between any two of those RPM values.
Drug Load
[0038] The drug load of each polymer microsphere in a drug to polymer ratio, expressed as a percentage, may be greater than 40 wt/wt%, including from about 40 wt/wt% to about 70 wt/wt%, from about 45 wt/wt% to about 70 wt/wt%, from about 45 wt/wt% to about 65 wt/wt%, from about 50 wt/wt% to about 65 wt/wt%, greater than 50 wt/wt%, and any value or range between any two of those drug loads.
[0039] In some particular aspects, it is contemplated that the drug load may be as low as 20 wt/wt%.
Particle Size
Particle Size
[0040] In one aspect, the polymer microspheres may have an average particle size of less than 110 i_tm (D5o), including between about 30 i_tm (D5o) and about 60 i_tm (D5o), between about 30 i_tm (D5o) and about 50 i_tm (D5o), between about 35 i_tm (D5o) and about 60 i_tm (D5o), between about 45 tm (D5o) and about 60 i_tm (D5o), about 30 im (D5o), about 35 i_tm (D5o), about 40 i_tm (D5o), about 45 i_tm (D5o), about 50 i_tm (D5o), about 55 i_tm (D5o), about 60 i_tm (D5o), less than about 60 jim (D5o), and any value or range between any two of those average particle sizes.
[0041] In some particular aspects, it is contemplated that average particle sizes may be as large as 150-200 m.
Extended Release
Extended Release
[0042] In one aspect, the microsphere formulations are characterized in that they have an in vivo duration of release of less than about 7 days in humans. In one aspect, the microsphere formulations are characterized in that they have an in vivo duration of release of between about 7 days to about 14 days in humans. In one aspect, the microsphere formulations are characterized in that they have an in vivo duration of release of between about 14 days to about 28 days in humans. In one aspect, the microsphere formulations are characterized in that they have an in vivo duration of release of about 28 days in humans. In one aspect, the microsphere formulations are characterized in that they have an in vivo duration of release of greater than about 28 days in humans.
[0043] In one aspect, the microsphere formulations are characterized in that at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or 100%, and any range between any of those values, of the BTK inhibitor is released within <7, 7-14, 14-28, or >28 days (as described in the preceding paragraph) of injection into a subject.
For example, in one aspect, the microsphere formulations are characterized in that about 75% to 100% of the BTK
inhibitor is released over the designated period after injection into a subject. In another aspect, the microsphere formulations are characterized in that they have a low initial burst release, that is, not more than about 20% of the BTK inhibitor is released within about 24 hours of injection into a subj ect.
For example, in one aspect, the microsphere formulations are characterized in that about 75% to 100% of the BTK
inhibitor is released over the designated period after injection into a subject. In another aspect, the microsphere formulations are characterized in that they have a low initial burst release, that is, not more than about 20% of the BTK inhibitor is released within about 24 hours of injection into a subj ect.
[0044] A further aspect includes a sustained release injectable formulation of ibrutinib that is pharmacologically comparable to oral doses of: 70 mg, 140 mg, 280 mg, 420 mg, and 560 mg, in sustained release injectable formulations that release over approximately 7, 14, 21, or 28 days.
[0045] Another aspect includes a method of treating a human patient for MCL, CLL/SLL, and other diseases or conditions that may be treated by the BTK inhibitors. The method may comprise providing an injectable form of ibrutinib in a dosage strength that is pharmacologically comparable to 70 mg, 140 mg, 280 mg, 420 mg, and 560 mg per day orally, the injectable form with a duration of continuous release such that patient compliance is assured, the medical consequences of missing a dose or doses are avoided, and the pharmacokinetic profile is improved as compared with the oral dosage form.
Therapeutic Benefits
Therapeutic Benefits
[0046] Possible conditions that may be treated using the microsphere formulations comprising a BTK inhibitor include cancer, including B-cell malignancies, including MCL, CCL, and SLL.
In one aspect, a B-cell malignancy may be treated using the microsphere formulations comprising a BTK inhibitor, wherein the microsphere formulations are administered about every <7, 7-14, 14-28, or >28 days.
In one aspect, a B-cell malignancy may be treated using the microsphere formulations comprising a BTK inhibitor, wherein the microsphere formulations are administered about every <7, 7-14, 14-28, or >28 days.
[0047] In one aspect, a method for treating cancer, including a B-cell malignancy, is provided.
The method may comprise administering by intramuscular or subcutaneous injection to a patient in need thereof a microsphere formulation made according to the methods described herein.
The method may comprise administering by intramuscular or subcutaneous injection to a patient in need thereof a microsphere formulation made according to the methods described herein.
[0048] In another aspect, use is disclosed of a microsphere formulation comprising polymer microspheres, each polymer microsphere comprising: (i) a BTK inhibitor; and (ii) a biodegradable polymer, wherein each polymer microsphere comprises a drug load of the BTK
inhibitor of greater than 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of less than 110 i_tm (D50), in the manufacture of a medicament for the treatment of cancer, including a B-cell malignancy.
inhibitor of greater than 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of less than 110 i_tm (D50), in the manufacture of a medicament for the treatment of cancer, including a B-cell malignancy.
[0049] In another aspect, a microsphere formulation comprising polymer microspheres, each polymer microsphere comprising: (i) a BTK inhibitor; and (ii) a biodegradable polymer, wherein each polymer microsphere comprises a drug load of the BTK inhibitor of greater than 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of less than 110 i_tm (D50), is provided for use as a medicament for the treatment of cancer, including a B-cell malignancy.
[0050] In another aspect, a kit is provided, the kit comprising polymer microspheres, each polymer microsphere comprising: (i) a BTK inhibitor; and (ii) a biodegradable polymer, wherein each polymer microsphere comprises a drug load of the BTK inhibitor of greater than 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of less than 110 i_tm (D50).
EXAMPLES
Example 1 ¨ General preparation of polymer microspheres comprising a BTK
inhibitor
EXAMPLES
Example 1 ¨ General preparation of polymer microspheres comprising a BTK
inhibitor
[0051] Microsphere Formation Phase. With reference to Figure 1, a dispersed phase ("DP") is formed by dissolving a polymer matrix (such as a PLGA or PLA polymer) in an organic solvent system (such as DCM), followed by the addition of the BTK inhibitor with mixing until completely dissolved. The DP 10 is filtered using a 0.2 i_tm sterilizing PTFE
or PVDF membrane filter (such as EMFLON, commercially available from Pall or SartoriousAG) and pumped into a homogenizer 30 at a defined flow rate. A continuous phase ("CP") 20 comprising water, surfactant, and, optionally, a buffer is also pumped into the homogenizer 30 at a defined flow rate.
The speed of the homogenizer 30 is generally fixed to achieve a desired polymer microsphere size distribution. A representative continuous "upstream" microsphere formation phase is described in U.S. Pat. No. 5,945,126, which is incorporated by reference herein in its entirety.
or PVDF membrane filter (such as EMFLON, commercially available from Pall or SartoriousAG) and pumped into a homogenizer 30 at a defined flow rate. A continuous phase ("CP") 20 comprising water, surfactant, and, optionally, a buffer is also pumped into the homogenizer 30 at a defined flow rate.
The speed of the homogenizer 30 is generally fixed to achieve a desired polymer microsphere size distribution. A representative continuous "upstream" microsphere formation phase is described in U.S. Pat. No. 5,945,126, which is incorporated by reference herein in its entirety.
[0052] Microsphere Processing Phase. The formed or forming microspheres exit the homogenizer 30 and enter a solvent removal vessel ("SRV") 40. Water may be added to the SRV
40 during microsphere formation to minimize the solvent level in the aqueous medium. See, e.g., U.S. Patent No. 9,017,715, which is incorporated by reference herein in its entirety. After the DP
has been exhausted, the CP 20 and water flow rates are stopped, and the washing steps are initiated. Solvent removal is achieved using water washing and a hollow fiber filter (commercially available as HFF from Cytiva) 50. A representative "downstream" microsphere processing phase is described in U.S. Pat. No. 6,270,802, which is incorporated by reference herein in its entirety.
40 during microsphere formation to minimize the solvent level in the aqueous medium. See, e.g., U.S. Patent No. 9,017,715, which is incorporated by reference herein in its entirety. After the DP
has been exhausted, the CP 20 and water flow rates are stopped, and the washing steps are initiated. Solvent removal is achieved using water washing and a hollow fiber filter (commercially available as HFF from Cytiva) 50. A representative "downstream" microsphere processing phase is described in U.S. Pat. No. 6,270,802, which is incorporated by reference herein in its entirety.
[0053] The washed microspheres are collected and freeze-dried in a lyophilizer (Virtis) to remove any moisture. The resulting microspheres are a free-flowing off-white bulk powder.
Example 2 ¨ Preparation of Ibrutinib-Encapsulated Polymer Microspheres Comprising a 50:50 PLGA ¨ Batch Nos. 1 and 2 ("Group A")
Example 2 ¨ Preparation of Ibrutinib-Encapsulated Polymer Microspheres Comprising a 50:50 PLGA ¨ Batch Nos. 1 and 2 ("Group A")
[0054] Following the general procedure described in Example 1 and illustrated in Figure 1, the DP was formed by dissolving 2.5 g of either 502 H polymer (Batch No. 1) or 502 polymer (Batch No. 2) (IV = 0.20 dL/g) in 11.67 g of DCM, followed by addition of ibrutinib (2.5 g) with mixing until completely dissolved. The DP was filtered and pumped at a flow rate of 25 mL/min into a Levitronix BPS-i100 integrated pump system operating at 3,000 RPM. The CP comprising 0.35% PVA was also pumped into the homogenizer at a flow rate of 2 L/min (CP:DP = 80:1).
[0055] The formed or forming microspheres exited the homogenizer and entered the SRV.
Deionized water was added to the SRV. Solvent removal was achieved using water washing and a hollow fiber filter. The bulk suspension was collected via filtration and lyophilized to obtain a free-flowing powder.
Deionized water was added to the SRV. Solvent removal was achieved using water washing and a hollow fiber filter. The bulk suspension was collected via filtration and lyophilized to obtain a free-flowing powder.
[0056] Batch No. 1 had an average particle size of 36 tm (D50), a drug load of 47.6 wt%, and a molecular weight of 17.6 kDa. The microspheres contained residual DCM of 3.0%. Batch No.
2 had an average particle size of 44 jim (D50), a drug load of 47.8 wt%, and a molecular weight of 17.7 kDa. The microspheres contained residual DCM of 3.0%. The parameters and results are shown tabularly in Table 1:
t Batch Number 1 2 = Symbol 0 A
Polymer Evonik Supplier/Name gCo-Monomer Ratio 50:50 rt' Polymer IV (dL/g) 0.20 E Polymer Endcap Acid Ester O Batch Size (g) 5 Mixing Speed (RPM) 3000 Target Drug Load (%) 50.0 Drug Load (%) 47.6 47.8 Encapsulation 95.2 95.6 Efficiency (%) Tzi Residual Solvent 3.0 3.0 = C- = D M (%) 13,10 17 18 = Particle Size 13,50 36 44 (11m) 13,90 59 79 Sample MW (kDa) 17.6 17.7 Polymer MW (kDa) 17.4 17.6 Table 1
2 had an average particle size of 44 jim (D50), a drug load of 47.8 wt%, and a molecular weight of 17.7 kDa. The microspheres contained residual DCM of 3.0%. The parameters and results are shown tabularly in Table 1:
t Batch Number 1 2 = Symbol 0 A
Polymer Evonik Supplier/Name gCo-Monomer Ratio 50:50 rt' Polymer IV (dL/g) 0.20 E Polymer Endcap Acid Ester O Batch Size (g) 5 Mixing Speed (RPM) 3000 Target Drug Load (%) 50.0 Drug Load (%) 47.6 47.8 Encapsulation 95.2 95.6 Efficiency (%) Tzi Residual Solvent 3.0 3.0 = C- = D M (%) 13,10 17 18 = Particle Size 13,50 36 44 (11m) 13,90 59 79 Sample MW (kDa) 17.6 17.7 Polymer MW (kDa) 17.4 17.6 Table 1
[0057] Figure 2 is a graph showing in vitro cumulative ibrutinib release over time from the Group A ibrutinib-encapsulating polymer microspheres.
Example 3 ¨ Preparation of Ibrutinib-Encapsulated Polymer Microspheres Comprising a 75:25 PLGA with a low polymer IV ¨ Batch Nos. 3, 4, 6, 7, and 11 ("Group B")
Example 3 ¨ Preparation of Ibrutinib-Encapsulated Polymer Microspheres Comprising a 75:25 PLGA with a low polymer IV ¨ Batch Nos. 3, 4, 6, 7, and 11 ("Group B")
[0058] Following the general procedure described in Example 1 and illustrated in Figure 1, the DP was formed by dissolving 2.5 g (Batch Nos. 3, 4, and 11), 2.0 g (Batch No. 6), or 1.5 g (Batch No. 7) of either 7503 A polymer (Batch Nos. 3, 6, 7, and 11) or 7502 E
polymer (Batch No. 6) (IV = 0.26 dL/g) in 11.67 g of DCM, followed by addition of ibrutinib (sufficient to provide a DP weight of 16.67 g, i.e., 2.5 g for Batch Nos. 3, 4, and 11; 3.0 g for Batch No. 6; and 3.5 g for Batch No. 7) with mixing until completely dissolved. The DP was filtered and pumped at a flow rate of 25 mL/min into a Levitronix BPS-i100 integrated pump system operating at 3,000 RPM
(Batch Nos. 3, 4, 6, and 7) or 2,000 RPM (Batch No. 11). The CP comprising 0.35% PVA was also pumped into the homogenizer at a flow rate of 2 L/min (CP:DP = 80:1).
polymer (Batch No. 6) (IV = 0.26 dL/g) in 11.67 g of DCM, followed by addition of ibrutinib (sufficient to provide a DP weight of 16.67 g, i.e., 2.5 g for Batch Nos. 3, 4, and 11; 3.0 g for Batch No. 6; and 3.5 g for Batch No. 7) with mixing until completely dissolved. The DP was filtered and pumped at a flow rate of 25 mL/min into a Levitronix BPS-i100 integrated pump system operating at 3,000 RPM
(Batch Nos. 3, 4, 6, and 7) or 2,000 RPM (Batch No. 11). The CP comprising 0.35% PVA was also pumped into the homogenizer at a flow rate of 2 L/min (CP:DP = 80:1).
[0059] The formed or forming microspheres exited the homogenizer and entered the SRV.
Deionized water was added to the SRV. Solvent removal was achieved using water washing and a hollow fiber filter. The bulk suspension was collected via filtration and lyophilized to obtain a free-flowing powder.
Deionized water was added to the SRV. Solvent removal was achieved using water washing and a hollow fiber filter. The bulk suspension was collected via filtration and lyophilized to obtain a free-flowing powder.
[0060] Batch No. 3 had an average particle size of 39 jim (D50), a drug load of 48.2 wt%, and a molecular weight of 29.4 kDa. The microspheres contained residual DCM of 3.1%. Batch No.
4 had an average particle size of 35 jim (D50), a drug load of 48.9 wt%, and a molecular weight of 25.5 kDa. The microspheres contained residual DCM of 2.1%. Batch No. 6 had an average particle size of 34 jim (D50), a drug load of 60.6 wt%, and a molecular weight of 31.0 kDa. The microspheres contained residual DCM of 2.7%. Batch No. 7 had an average particle size of 30 jim (D50), a drug load of 65.6 wt%, and a molecular weight of 30.1 kDa. The microspheres contained residual DCM of 1.5%. Batch No. 11 had an average particle size of
4 had an average particle size of 35 jim (D50), a drug load of 48.9 wt%, and a molecular weight of 25.5 kDa. The microspheres contained residual DCM of 2.1%. Batch No. 6 had an average particle size of 34 jim (D50), a drug load of 60.6 wt%, and a molecular weight of 31.0 kDa. The microspheres contained residual DCM of 2.7%. Batch No. 7 had an average particle size of 30 jim (D50), a drug load of 65.6 wt%, and a molecular weight of 30.1 kDa. The microspheres contained residual DCM of 1.5%. Batch No. 11 had an average particle size of
61 jim (D5o), a drug load of 51 wt%, and a molecular weight of 28.9 kDa. The microspheres contained residual DCM of 1.4%. The parameters and results are shown tabularly in Table 2:
t Batch Number 3 4 6 7 11 Symbol o A o 0 X
Polymer Ashland Supplier/Name Co-Monomer 75:25 Ratio () Polymer IV
0.26 2, (dL/g) ct Polymer Acid Ester Acid ! Endcap o 4-1 Batch Size (g) 5 Mixing Speed (RPM) Target Drug 50.0 50.0 60.0 70.0 50.0 Load (%) Drug Load 48.2 48.9 60.6 65.6 51.0 (A) Encapsulation 96.4 97.8 101.0 93.7 102.0 Efficiency (%) Residual Tzi Solvent DCM 3.1 2.1 2.7 1.5 1.4 .-7-,' (%) -c-zd Particle Dv10 17 15 12 10 29 Size Dv50 39 35 34 30 61 (111n) Dv90 65 59 58 53 103 Sample MW
29.4 25.5 31.0 30.1 28.9 (kDa) Polymer MW
30.7 25.8 30.7 30.7 28.6 _(kDa) Table 2 [0061] Figure 3 is a graph showing in vitro cumulative ibrutinib release over time from the Group B ibrutinib-encapsulating polymer microspheres.
Example 4 ¨ Preparation of Ibrutinib-Encapsulated Polymer Microspheres Comprising a 75:25 PLGA with a high polymer IV ¨ Batch Nos. 5, 12, 13, and 14 ("Group C")
t Batch Number 3 4 6 7 11 Symbol o A o 0 X
Polymer Ashland Supplier/Name Co-Monomer 75:25 Ratio () Polymer IV
0.26 2, (dL/g) ct Polymer Acid Ester Acid ! Endcap o 4-1 Batch Size (g) 5 Mixing Speed (RPM) Target Drug 50.0 50.0 60.0 70.0 50.0 Load (%) Drug Load 48.2 48.9 60.6 65.6 51.0 (A) Encapsulation 96.4 97.8 101.0 93.7 102.0 Efficiency (%) Residual Tzi Solvent DCM 3.1 2.1 2.7 1.5 1.4 .-7-,' (%) -c-zd Particle Dv10 17 15 12 10 29 Size Dv50 39 35 34 30 61 (111n) Dv90 65 59 58 53 103 Sample MW
29.4 25.5 31.0 30.1 28.9 (kDa) Polymer MW
30.7 25.8 30.7 30.7 28.6 _(kDa) Table 2 [0061] Figure 3 is a graph showing in vitro cumulative ibrutinib release over time from the Group B ibrutinib-encapsulating polymer microspheres.
Example 4 ¨ Preparation of Ibrutinib-Encapsulated Polymer Microspheres Comprising a 75:25 PLGA with a high polymer IV ¨ Batch Nos. 5, 12, 13, and 14 ("Group C")
[0062] Following the general procedure described in Example 1 and illustrated in Figure 1, the DP was formed by dissolving 2.5 g (Batch Nos. 5 and 12) or 2.0 g (Batch Nos. 13 and 14) of either 7505 A polymer (Batch No. 5) (IV = 0.56 dL/g), 7505 E polymer (Batch No. 12) (IV = 0.41 dL/g), 7507 A polymer (Batch No. 13) (IV = 0.7 dL/g), or 7507 E polymer (Batch No. 14) (IV =
0.66 dL/g) in 11.67 g of DCM, followed by addition of ibrutinib (sufficient to provide a DP weight of 16.67 g, i.e., 2.5 g for Batch Nos. 5 and 12; and 3.0 g for Batch Nos. 13 and 14) with mixing until completely dissolved. The DP was filtered and pumped at a flow rate of 25 mL/min into a Levitronix BPS-i100 integrated pump system operating at 3,000 RPM. The CP
comprising 0.35% PVA was also pumped into the homogenizer at a flow rate of 2 L/min (CP:DP = 80:1).
0.66 dL/g) in 11.67 g of DCM, followed by addition of ibrutinib (sufficient to provide a DP weight of 16.67 g, i.e., 2.5 g for Batch Nos. 5 and 12; and 3.0 g for Batch Nos. 13 and 14) with mixing until completely dissolved. The DP was filtered and pumped at a flow rate of 25 mL/min into a Levitronix BPS-i100 integrated pump system operating at 3,000 RPM. The CP
comprising 0.35% PVA was also pumped into the homogenizer at a flow rate of 2 L/min (CP:DP = 80:1).
[0063] The formed or forming microspheres exited the homogenizer and entered the SRV.
Deionized water was added to the SRV. Solvent removal was achieved using water washing and a hollow fiber filter. The bulk suspension was collected via filtration and lyophilized to obtain a free-flowing powder.
Deionized water was added to the SRV. Solvent removal was achieved using water washing and a hollow fiber filter. The bulk suspension was collected via filtration and lyophilized to obtain a free-flowing powder.
[0064] Batch No. 5 had an average particle size of 53 jim (D5o), a drug load of 47.5 wt%, and a molecular weight of 66.4 kDa. The microspheres contained residual DCM of 4.1%. Batch No.
12 had an average particle size of 47 jim (D5o), a drug load of 51.2 wt%, and a molecular weight of 49.8 kDa. The microspheres contained residual DCM of 0.8%. Batch No. 13 had an average particle size of 52 jim (D5o), a drug load of 62.2 wt%, and a molecular weight of 87.7 kDa. The microspheres contained residual DCM of 1.3%. Batch No. 14 had an average particle size of 53 jim (D5o), a drug load of 61.0 wt%, and a molecular weight of 90.8 kDa. The microspheres contained residual DCM of 1.3%. The parameters and results are shown tabularly in Table 3:
t Batch Number 5 12 13 14 Symbol o A 0 Polymer Ashland Supplier/Name Co-Monomer Ratio () Polymer IV
0.56 0.41 0.70 0.66 ct Polymer Acid Ester Acid Ester Endcap 4-1 Batch Size (g) 5 Mixing Speed (RPM) Target Drug 50.0 60.0 Load (%) Drug Load 47.5 51.2 62.2 61.0 (%) Encapsulation 95.0 102.4 103.7 101.7 Efficiency (%) Residual Tzi Solvent DCM 4.1 0.8 1.3 1.3 c.) (%) -c-zd Particle Dv10 15 17 14 15 Size Dv50 53 47 52 53 (un) Dv90 102 84 106 106 Sample MW
66.4 49.8 87.7 90.8 (kDa) Polymer MW
66.2 50.0 91.0 92.9 (kDa) Table 3
12 had an average particle size of 47 jim (D5o), a drug load of 51.2 wt%, and a molecular weight of 49.8 kDa. The microspheres contained residual DCM of 0.8%. Batch No. 13 had an average particle size of 52 jim (D5o), a drug load of 62.2 wt%, and a molecular weight of 87.7 kDa. The microspheres contained residual DCM of 1.3%. Batch No. 14 had an average particle size of 53 jim (D5o), a drug load of 61.0 wt%, and a molecular weight of 90.8 kDa. The microspheres contained residual DCM of 1.3%. The parameters and results are shown tabularly in Table 3:
t Batch Number 5 12 13 14 Symbol o A 0 Polymer Ashland Supplier/Name Co-Monomer Ratio () Polymer IV
0.56 0.41 0.70 0.66 ct Polymer Acid Ester Acid Ester Endcap 4-1 Batch Size (g) 5 Mixing Speed (RPM) Target Drug 50.0 60.0 Load (%) Drug Load 47.5 51.2 62.2 61.0 (%) Encapsulation 95.0 102.4 103.7 101.7 Efficiency (%) Residual Tzi Solvent DCM 4.1 0.8 1.3 1.3 c.) (%) -c-zd Particle Dv10 15 17 14 15 Size Dv50 53 47 52 53 (un) Dv90 102 84 106 106 Sample MW
66.4 49.8 87.7 90.8 (kDa) Polymer MW
66.2 50.0 91.0 92.9 (kDa) Table 3
[0065] Figure 4 is a graph showing in vitro cumulative ibrutinib release over time from the Group C ibrutinib-encapsulating polymer microspheres.
Example 5 ¨ Preparation of Ibrutinib-Encapsulated Polymer Microspheres Comprising an 85:15 PLGA ¨ Batch Nos. 18 and 19 ("Group D")
Example 5 ¨ Preparation of Ibrutinib-Encapsulated Polymer Microspheres Comprising an 85:15 PLGA ¨ Batch Nos. 18 and 19 ("Group D")
[0066] Following the general procedure described in Example 1 and illustrated in Figure 1, the DP was formed by dissolving 2.5 g of either 8503 A polymer (Batch No. 18) (IV = 0.24 dL/g) or 8503 E polymer (Batch No. 19) (IV = 0.25 dL/g) in 11.67 g of DCM, followed by addition of ibrutinib (2.5 g) with mixing until completely dissolved. The DP was filtered and pumped at a flow rate of 25 mL/min into a Levitronix BPS-i100 integrated pump system operating at 3,000 RPM. The CP comprising 0.35% PVA was also pumped into the homogenizer at a flow rate of 2 L/min (CP:DP = 80:1).
[0067] The formed or forming microspheres exited the homogenizer and entered the SRV.
Deionized water was added to the SRV. Solvent removal was achieved using water washing and a hollow fiber filter. The bulk suspension was collected via filtration and lyophilized to obtain a free-flowing powder.
Deionized water was added to the SRV. Solvent removal was achieved using water washing and a hollow fiber filter. The bulk suspension was collected via filtration and lyophilized to obtain a free-flowing powder.
[0068] Batch No. 18 had an average particle size of 36 jim (D5o), a drug load of 49.8 wt%, and a molecular weight of 22.7 kDa. The microspheres contained residual DCM of 0.5%. Batch No.
19 had an average particle size of 35 jim (D5o), a drug load of 49.2 wt%, and a molecular weight of 25.8 kDa. The microspheres contained residual DCM of 0.3%. The parameters and results are shown tabularly in Table 4:
t Batch Number 18 19 Symbol 0 Polymer Ashland Supplier/Name Co-Monomer Ratio 85:15 2, Polymer IV (dL/g) 0.24 0.25 ct = Polymer Endcap Acid Ester Batch Size (g) 5 4-1 Mixing Speed (RPM) 3000 Target Drug Load (%) Drug Load (%) 49.8 49.2 Encapsulation o 99.6 98.4 Efficiency (%) -c-d Residual Solvent = DCM (%) 0.5 0.3 Particle Size Dv10 15 13 (11m) 130,50 36 35 130,90 62 61 Sample MW (kDa) 22.7 25.8 Polymer MW (kDa) 22.7 26.4 Table 4
19 had an average particle size of 35 jim (D5o), a drug load of 49.2 wt%, and a molecular weight of 25.8 kDa. The microspheres contained residual DCM of 0.3%. The parameters and results are shown tabularly in Table 4:
t Batch Number 18 19 Symbol 0 Polymer Ashland Supplier/Name Co-Monomer Ratio 85:15 2, Polymer IV (dL/g) 0.24 0.25 ct = Polymer Endcap Acid Ester Batch Size (g) 5 4-1 Mixing Speed (RPM) 3000 Target Drug Load (%) Drug Load (%) 49.8 49.2 Encapsulation o 99.6 98.4 Efficiency (%) -c-d Residual Solvent = DCM (%) 0.5 0.3 Particle Size Dv10 15 13 (11m) 130,50 36 35 130,90 62 61 Sample MW (kDa) 22.7 25.8 Polymer MW (kDa) 22.7 26.4 Table 4
[0069] Figure 5 is a graph showing in vitro cumulative ibrutinib release over time from the Group D ibrutinib-encapsulating polymer microspheres.
Example 6 ¨ Preparation of Ibrutinib-Encapsulated Polymer Microspheres Comprising a PLA ¨
Batch Nos. 8, 9, 10, 16, and 17 ("Group E")
Example 6 ¨ Preparation of Ibrutinib-Encapsulated Polymer Microspheres Comprising a PLA ¨
Batch Nos. 8, 9, 10, 16, and 17 ("Group E")
[0070] Following the general procedure described in Example 1 and illustrated in Figure 1, the DP was formed by dissolving 2.5 g (Batch Nos. 8, 9, 16, and 17) or 2.0 g (Batch No. 10) of either DL 02 A polymer (Batch Nos. 8 and 17) (IV = 0.16 dL/g), DL 02 E polymer (Batch Nos. 9 and 10) (IV = 0.18 dL/g), or DL 03 A polymer (Batch No. 16) (IV = 0.32 dL/g) in 11.67 g of DCM, followed by addition of ibrutinib (sufficient to provide a DP weight of 16.67 g, i.e., 2.5 g for Batch Nos. 8, 9, 16, and 17; and 3.0 g for Batch No. 10) with mixing until completely dissolved. The DP was filtered and pumped at a flow rate of 25 mL/min into a Levitronix BPS-i100 integrated pump system operating at either 3,000 RPM (Batch Nos. 8, 9, 10, and 16) or 2,000 RPM (Batch No. 17). The CP comprising 0.35% PVA was also pumped into the homogenizer at a flow rate of 2 L/min (CP:DP = 80:1).
[0071] The formed or forming microspheres exited the homogenizer and entered the SRV.
Deionized water was added to the SRV. Solvent removal was achieved using water washing and a hollow fiber filter. The bulk suspension was collected via filtration and lyophilized to obtain a free-flowing powder.
Deionized water was added to the SRV. Solvent removal was achieved using water washing and a hollow fiber filter. The bulk suspension was collected via filtration and lyophilized to obtain a free-flowing powder.
[0072] Batch No. 8 had an average particle size of 32 i_tm (D5o), a drug load of 51.7 wt%, and a molecular weight of 12.0 kDa. The microspheres contained residual DCM of 0.4%. Batch No.
9 had an average particle size of 29 i_tm (D50), a drug load of 51.8 wt%, and a molecular weight of 11.7 kDa. The microspheres contained residual DCM of 0.1%. Batch No. 10 had an average particle size of 29 i_tm (D50), a drug load of 64.2 wt%, and a molecular weight of 11.7 kDa. The microspheres contained residual DCM of 0.2%. Batch No. 16 had an average particle size of 40 i_tm (D50), a drug load of 48.9 wt%, and a molecular weight of 30.1 kDa. The microspheres contained residual DCM of 0.6%. Batch No. 17 had an average particle size of 49 i_tm (D5o), a drug load of 50.2 wt%, and a molecular weight of 12.4 kDa. The microspheres contained residual DCM of 0.8%. The parameters and results are shown tabularly in Table 5:
t Batch Number 8 9 10 16 17 = Symbol o A o 0 X
Polymer Ashland Supplier/Name Co-Monomer Ratio () Polymer IV
0.16 0.18 0.32 0.16 =,72, (dL/g) ct Polymer Acid Ester Acid ! Endcap o 4-1 Batch Size (g) 5 Mixing Speed (RPM) Target Drug 50.0 60.0 50.0 Load (%) Drug Load 51.7 51.8 64.2 48.9 50.2 (%) Encapsulation 103.4 103.6 107.0 97.8 100.4 Efficiency (%) Tzi Residual c.) = Solvent DCM 0.4 0.1 0.2 0.6 0.8 '' Particle Dv10 15 12 14 18 25 Size Dv50 32 29 29 40 49 (111n) Dv90 53 50 50 66 81 Sample MW
12.0 11.7 11.7 30.1 12.4 _(kDa) Polymer MW
11.9 11.8 11.8 29.5 11.7 (kD a) Table 5
9 had an average particle size of 29 i_tm (D50), a drug load of 51.8 wt%, and a molecular weight of 11.7 kDa. The microspheres contained residual DCM of 0.1%. Batch No. 10 had an average particle size of 29 i_tm (D50), a drug load of 64.2 wt%, and a molecular weight of 11.7 kDa. The microspheres contained residual DCM of 0.2%. Batch No. 16 had an average particle size of 40 i_tm (D50), a drug load of 48.9 wt%, and a molecular weight of 30.1 kDa. The microspheres contained residual DCM of 0.6%. Batch No. 17 had an average particle size of 49 i_tm (D5o), a drug load of 50.2 wt%, and a molecular weight of 12.4 kDa. The microspheres contained residual DCM of 0.8%. The parameters and results are shown tabularly in Table 5:
t Batch Number 8 9 10 16 17 = Symbol o A o 0 X
Polymer Ashland Supplier/Name Co-Monomer Ratio () Polymer IV
0.16 0.18 0.32 0.16 =,72, (dL/g) ct Polymer Acid Ester Acid ! Endcap o 4-1 Batch Size (g) 5 Mixing Speed (RPM) Target Drug 50.0 60.0 50.0 Load (%) Drug Load 51.7 51.8 64.2 48.9 50.2 (%) Encapsulation 103.4 103.6 107.0 97.8 100.4 Efficiency (%) Tzi Residual c.) = Solvent DCM 0.4 0.1 0.2 0.6 0.8 '' Particle Dv10 15 12 14 18 25 Size Dv50 32 29 29 40 49 (111n) Dv90 53 50 50 66 81 Sample MW
12.0 11.7 11.7 30.1 12.4 _(kDa) Polymer MW
11.9 11.8 11.8 29.5 11.7 (kD a) Table 5
[0073] Figure 6 is a graph showing in vitro cumulative ibrutinib release over time from the Group E ibrutinib-encapsulating polymer microspheres.
[0074] In use, the microspheres may be suspended in a diluent for administration (injection).
The diluent may generally contain a thickening agent, a tonicity agent, and a wetting agent. The thickening agent may include carboxymethyl cellulose-sodium (CMC-Na) or other suitable compounds. An appropriate viscosity grade and suitable concentration of CMC-Na may be selected so that the viscosity of the diluent is 3 cps or higher. Generally, a viscosity of about 10 cps is suitable; however, a higher viscosity diluent may be preferred for larger microspheres to minimize the settling of microspheres in the suspension.
The diluent may generally contain a thickening agent, a tonicity agent, and a wetting agent. The thickening agent may include carboxymethyl cellulose-sodium (CMC-Na) or other suitable compounds. An appropriate viscosity grade and suitable concentration of CMC-Na may be selected so that the viscosity of the diluent is 3 cps or higher. Generally, a viscosity of about 10 cps is suitable; however, a higher viscosity diluent may be preferred for larger microspheres to minimize the settling of microspheres in the suspension.
[0075] Uniform microsphere suspension without particle settling will result in a consistent delivered dose during drug administration by injection. To have a tonicity of the diluent closer to the biological system, about 290 milliosmole (mOsm), solutes such as mannitol, sodium chloride, or any other acceptable salt may be used. The diluent may also contain a buffer salt to maintain the pH of the composition. Typically, the pH is maintained around a physiologically relevant pH
by adjusting the buffer content as needed (pH about 7 to about 8).
by adjusting the buffer content as needed (pH about 7 to about 8).
[0076] The aspects disclosed herein are not intended to be exhaustive or to be limiting. A
skilled artisan would acknowledge that other aspects or modifications to instant aspects can be made without departing from the spirit or scope of the invention. The aspects of the present disclosure, as generally described herein and illustrated in the figures, can be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are contemplated herein.
skilled artisan would acknowledge that other aspects or modifications to instant aspects can be made without departing from the spirit or scope of the invention. The aspects of the present disclosure, as generally described herein and illustrated in the figures, can be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are contemplated herein.
[0077] Unless otherwise specified, "a," "an," "the," "one or more of," and "at least one" are used interchangeably. The singular forms "a", "an," and "the" are inclusive of their plural forms.
The recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.). The terms "comprising" and "including"
are intended to be equivalent and open-ended. The phrase "consisting essentially of' means that the composition or method may include additional ingredients and/or steps, but only if the additional ingredients and/or steps do not materially alter the basic and novel characteristics of the claimed composition or method. The phrase "selected from the group consisting of' is meant to include mixtures of the listed group.
The recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.). The terms "comprising" and "including"
are intended to be equivalent and open-ended. The phrase "consisting essentially of' means that the composition or method may include additional ingredients and/or steps, but only if the additional ingredients and/or steps do not materially alter the basic and novel characteristics of the claimed composition or method. The phrase "selected from the group consisting of' is meant to include mixtures of the listed group.
[0078] When reference is made to the term "each," it is not meant to mean "each and every, without exception." For example, if reference is made to microsphere formulation comprising polymer microspheres, and "each polymer microsphere" is said to have a particular BTK inhibitor content, if there are 10 polymer microspheres, and two or more of the polymer microspheres have the particular BTK inhibitor content, then that subset of two or more polymer microspheres is intended to meet the limitation.
[0079] The term "about" in conjunction with a number is simply shorthand and is intended to include 10% of the number. This is true whether "about" is modifying a stand-alone number or modifying a number at either or both ends of a range of numbers. In other words, "about 10"
means from 9 to 11. Likewise, "about 10 to about 20" contemplates 9 to 22 and 11 to 18. In the absence of the term "about," the exact number is intended. In other words, "10" means 10.
means from 9 to 11. Likewise, "about 10 to about 20" contemplates 9 to 22 and 11 to 18. In the absence of the term "about," the exact number is intended. In other words, "10" means 10.
Claims (24)
1. A microsphere formulation, comprising:
polymer microspheres, each polymer microsphere comprising:
a BTK inhibitor; and (ii) a biodegradable polymer, wherein each polymer microsphere comprises a drug load of the BTK inhibitor of greater than 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of less than pin (D5o).
polymer microspheres, each polymer microsphere comprising:
a BTK inhibitor; and (ii) a biodegradable polymer, wherein each polymer microsphere comprises a drug load of the BTK inhibitor of greater than 40% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of less than pin (D5o).
2. The microsphere formulation of claim 1, wherein the BTK inhibitor comprises ibrutinib.
3. The microsphere formulation of claim 1 or 2, wherein the biodegradable polymer comprises a poly(D,L-lactide-co-glycolide).
4. The microsphere formulation of any of claims 1-3, wherein the biodegradable polymer comprises a poly(D,L-lactide-co-glycolide) having a lactide:glycolide ratio of 50:50.
5. The microsphere formulation of any of claims 1-3, wherein the biodegradable polymer comprises a poly(D,L-lactide-co-glycolide) having a lactide:glycolide ratio of 75:25.
6. The microsphere formulation of any of claims 1-3, wherein the biodegradable polymer comprises a poly(D,L-lactide-co-glycolide) having a lactide:glycolide ratio of 85:15.
7. The microsphere formulation of claim 1 or 2, wherein the biodegradable polymer comprises a poly(D,L-lactide).
8. The microsphere formulation of any of the preceding claims, wherein the biodegradable polymer is acid-terminated.
9. The microsphere formulation of any of claims 1-7, wherein the biodegradable polymer is ester-terminated.
10. The microsphere formulation of any of claims 1-6, 8, or 9, wherein the biodegradable polymer has an inherent viscosity between about 0.2 dL/g and 0.6 dL/g.
11. The microsphere formulation of any of claims 1, 2, 7, 8, or 9, wherein the biodegradable polymer has an inherent viscosity between about 0.1 dL/g and 0.4 dL/g.
12. The microsphere formulation of any of the preceding claims, wherein each polymer microsphere comprises a drug load of the BTK inhibitor of from about 45% to about 65% by weight of the polymer microsphere.
13. The microsphere formulation of any of the preceding claims, wherein the polymer microspheres have an average particle size of about 30 m (D5o) to about 60 m (D5o).
14. The microsphere formulation of any of the preceding claims, characterized in that about 75% to 100% of the BTK inhibitor is released over a period of between about 7 and 28 days of injection into a subject, but not more than about 20% of the BTK inhibitor has been released within about 24 hours of injection into the subject.
15. A pharmaceutical composition comprising the microsphere formulation of any of the preceding claims.
16. The microsphere formulation of any of the preceding claims for use in the treatment of a B-cell malignancy.
17. A method for making a microsphere formulation, the method comprising the steps:
(i) contacting a BTK inhibitor with a biodegradable polymer comprising a poly(D,L-lactide-co-glycolide) having a co-monomer ratio of between about 50:50 and 85:15 and an inherent viscosity of between about 0.2 dL/g and 0.6 dL/g in the presence of an organic solvent system to form a dispersed phase;
(ii) combining the dispersed phase with a continuous phase comprising water and surfactant in a homogenizer to form an emulsion;
(iii) removing the organic solvent from the emulsion to form a microsphere formulation essentially free of organic solvent; and (iv) subjecting the substantially organic solvent-free microsphere formulation to a drying process.
(i) contacting a BTK inhibitor with a biodegradable polymer comprising a poly(D,L-lactide-co-glycolide) having a co-monomer ratio of between about 50:50 and 85:15 and an inherent viscosity of between about 0.2 dL/g and 0.6 dL/g in the presence of an organic solvent system to form a dispersed phase;
(ii) combining the dispersed phase with a continuous phase comprising water and surfactant in a homogenizer to form an emulsion;
(iii) removing the organic solvent from the emulsion to form a microsphere formulation essentially free of organic solvent; and (iv) subjecting the substantially organic solvent-free microsphere formulation to a drying process.
18. The method of claim 17, wherein the surfactant comprises polyvinyl alcohol.
19. The method of claim 17 or 18, wherein the surfactant comprises polyvinyl alcohol, and wherein the polyvinyl alcohol concentration in the aqueous phase prior to the combining is about 0.35% by weight.
20. A method for making a microsphere formulation, the method comprising the steps:
(i) contacting a BTK inhibitor with a biodegradable polymer comprising a poly(D,L-lactide) having an inherent viscosity of between about 0.1 dL/g and 0.4 dL/g in the presence of an organic solvent system to form a dispersed phase;
(ii) combining the dispersed phase with a continuous phase comprising water and surfactant in a homogenizer to form an emulsion;
(iii) removing the organic solvent from the emulsion to form a microsphere formulation essentially free of organic solvent; and (iv) subjecting the substantially organic solvent-free microsphere formulation to a drying process.
(i) contacting a BTK inhibitor with a biodegradable polymer comprising a poly(D,L-lactide) having an inherent viscosity of between about 0.1 dL/g and 0.4 dL/g in the presence of an organic solvent system to form a dispersed phase;
(ii) combining the dispersed phase with a continuous phase comprising water and surfactant in a homogenizer to form an emulsion;
(iii) removing the organic solvent from the emulsion to form a microsphere formulation essentially free of organic solvent; and (iv) subjecting the substantially organic solvent-free microsphere formulation to a drying process.
21. The method of claim 20, wherein the surfactant comprises polyvinyl alcohol.
22. The method of claim 20 or 21, wherein the surfactant comprises polyvinyl alcohol, and wherein the polyvinyl alcohol concentration in the aqueous phase prior to the combining is about 0.35% by weight.
23. A kit, comprising:
polymer microspheres, each polymer microsphere comprising:
ibrutinib; and (ii) a biodegradable polymer comprising a poly(D,L-lactide-co-glycolide) having an inherent viscosity between about 0.2 dL/g and 0.6 dL/g, wherein each polymer microsphere comprises a drug load of ibrutinib of from about 45% to about 65% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of from about 30 m (D5o) to about 60 m (D5o).
polymer microspheres, each polymer microsphere comprising:
ibrutinib; and (ii) a biodegradable polymer comprising a poly(D,L-lactide-co-glycolide) having an inherent viscosity between about 0.2 dL/g and 0.6 dL/g, wherein each polymer microsphere comprises a drug load of ibrutinib of from about 45% to about 65% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of from about 30 m (D5o) to about 60 m (D5o).
24. A method for treating a B-cell malignancy, the method comprising:
administering by intramuscular or subcutaneous injection to the subject a microsphere formulation with a dosing schedule of from about every 7 to about every 28 days, the microsphere formulation comprising:
ibrutinib; and (ii) a biodegradable polymer comprising a poly(D,L-lactide-co-glycolide) having an inherent viscosity between about 0.2 dL/g and 0.6 dL/g, wherein each polymer microsphere comprises a drug load of ibrutinib of from about 45% to about 65% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of about 30 m (D5o) to about 60 m (D5o).
administering by intramuscular or subcutaneous injection to the subject a microsphere formulation with a dosing schedule of from about every 7 to about every 28 days, the microsphere formulation comprising:
ibrutinib; and (ii) a biodegradable polymer comprising a poly(D,L-lactide-co-glycolide) having an inherent viscosity between about 0.2 dL/g and 0.6 dL/g, wherein each polymer microsphere comprises a drug load of ibrutinib of from about 45% to about 65% by weight of the polymer microsphere, and wherein the polymer microspheres have an average particle size of about 30 m (D5o) to about 60 m (D5o).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163156020P | 2021-03-03 | 2021-03-03 | |
US63/156,020 | 2021-03-03 | ||
PCT/US2022/070910 WO2022187822A1 (en) | 2021-03-03 | 2022-03-02 | Microsphere formulations comprising btk inhibitors and methods for making and using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3210001A1 true CA3210001A1 (en) | 2022-09-09 |
Family
ID=83154668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3210001A Pending CA3210001A1 (en) | 2021-03-03 | 2022-03-02 | Microsphere formulations comprising btk inhibitors and methods for making and using the same |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4301345A1 (en) |
JP (1) | JP2024508863A (en) |
KR (1) | KR20230154222A (en) |
CN (1) | CN116916893A (en) |
AU (1) | AU2022228489A1 (en) |
CA (1) | CA3210001A1 (en) |
IL (1) | IL304654A (en) |
MX (1) | MX2023010196A (en) |
WO (1) | WO2022187822A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9636308B2 (en) * | 2013-03-15 | 2017-05-02 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
MX2017001671A (en) * | 2014-08-07 | 2017-07-04 | Pharmacyclics Llc | Novel formulations of a bruton's tyrosine kinase inhibitor. |
-
2022
- 2022-03-02 AU AU2022228489A patent/AU2022228489A1/en active Pending
- 2022-03-02 CN CN202280014052.7A patent/CN116916893A/en active Pending
- 2022-03-02 JP JP2023552544A patent/JP2024508863A/en active Pending
- 2022-03-02 EP EP22764259.2A patent/EP4301345A1/en active Pending
- 2022-03-02 KR KR1020237033397A patent/KR20230154222A/en unknown
- 2022-03-02 WO PCT/US2022/070910 patent/WO2022187822A1/en active Application Filing
- 2022-03-02 CA CA3210001A patent/CA3210001A1/en active Pending
- 2022-03-02 MX MX2023010196A patent/MX2023010196A/en unknown
-
2023
- 2023-07-23 IL IL304654A patent/IL304654A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20230154222A (en) | 2023-11-07 |
MX2023010196A (en) | 2023-09-11 |
JP2024508863A (en) | 2024-02-28 |
EP4301345A1 (en) | 2024-01-10 |
WO2022187822A1 (en) | 2022-09-09 |
CN116916893A (en) | 2023-10-20 |
AU2022228489A1 (en) | 2023-08-17 |
IL304654A (en) | 2023-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180177785A1 (en) | Method of Making Sustained Release Microparticles | |
JP2016513721A (en) | High drug-containing buprenorphine microspheres and method for producing the same | |
Khang et al. | Local drug delivery system using biodegradable polymers | |
WO2010119455A2 (en) | An injectable sustained release pharmaceutical composition | |
KR20220112737A (en) | Long-lasting composition comprising rivastigmine and method for preparing the same | |
US9636308B2 (en) | High drug load buprenorphine microspheres and method of producing same | |
WO2022198167A1 (en) | Microsphere formulations comprising naltrexone and methods for making and using the same | |
CA3210001A1 (en) | Microsphere formulations comprising btk inhibitors and methods for making and using the same | |
US20240216280A1 (en) | Microsphere formulations comprising nalmefene andmethods for making and using the same | |
US20220054420A1 (en) | Microsphere formulations comprising ketamine and methods for making and using the same | |
US20230404922A1 (en) | Microsphere formulations comprising btk inhibitors and methods for making and using the same | |
US20240000772A1 (en) | Microsphere formulations comprising naltrexone and methods for making and using the same | |
US11992559B2 (en) | Microsphere formulations comprising lurasidone and methods for making and using the same | |
WO2024163997A1 (en) | Microsphere formulations comprising naltrexone and methods for making and using the same | |
US20240307381A1 (en) | Microsphere formulations comprising lurasidone and methods for making and using the same | |
WO2023097204A1 (en) | Microsphere formulations comprising asenapine and methods for making and using the same | |
WO2024097696A1 (en) | Mixed release profile polymer microsphere formulations comprising octreotide and methods for making and using the same | |
US20230225993A1 (en) | Microsphere formulations comprising ketamine and methods for making and using the same | |
WO2023133554A2 (en) | Microsphere formulations comprising ketamine and methods for making and using the same | |
RU2789057C2 (en) | COMPOSITIONS AND METHODS FOR LONG-TERM RELEASE OF ANTAGONISTS OF GONADOTROPIN-RELEASING HORMONE (GnRH) | |
CN116916920A (en) | Microsphere formulations comprising lurasidone and methods of making and using the same | |
WO2021199077A1 (en) | Risperidone microspheres, process for their prepartion and uses thereof |